BioMedWire Stocks

Potential Complications of Untreated Psoriasis

Psoriasis is a skin condition that causes individuals to develop a rash with scaly, itchy patches on their elbows, knees, trunk and scalp. This chronic illness, which may start off as a few itchy patches, can severely affect an individual’s quality of life.

Psoriasis is often accompanied by chronic inflammation, which affects those with mild and severe cases alike. Experts agree that in the absence of a cure, proper treatment is required to manage the condition.

Below we look at what happens when psoriasis remains untreated and any complications that may arise from undertreating or not treating the condition.

What to expect in the short- and long-term for untreated psoriasis?

Given that the condition causes itching in the beginning, it makes sense that leaving psoriasis untreated in the short-term will result in even more itching and discomfort. Spectrum Skin and Laser founder and dermatologic surgeon, Dr. Jeremy Brauer, states that intense itching will result in opened lesions that can become infected.

Psoriasis may also affect other organ systems, including the heart and cardiovascular system, as well as the skeletal system and the joints. This means that improper or no treatment heighten an individual’s health risks.

In addition to this, Brauer highlights that psoriasis that isn’t treated may also affect persons psychologically because it takes a physical and emotional toll and impairs a person’s quality of life, which in turn affects relationships and ability to perform daily tasks.

Patients who do not undergo treatment may also notice the presence of new patches on their body.

If psoriasis remains untreated in the long-term, other complications may begin to set in. Those complications include joint pain, chronic inflammation and limited mobility around the area affected.

Additionally, some comorbidities may be caused or worsened by untreated psoriasis. They include:

Psoriatic arthritis

Inflammation worsening in patients with psoriasis may develop into psoriatic arthritis. Recent studies have found that the possibility of the condition becoming arthritic is 20% after three decades. Mount Sinai Hospital dermatologist, Dr. Carmen Castilla, adds that patients with psoriatic arthritis may also suffer from permanent joint damage if they don’t undergo treatment.

Nonalcoholic fatty liver disease

Findings published in “Advances in Dermatology and Allergology” highlight that an individual’s risk of fatty liver disease increases if they have psoriasis.

Kidney disease

Research has also determined that psoriasis patients had a considerably higher risk of developing chronic kidney disease and end-state renal disease. This link may boil down to the fact that psoriatic patients have a heightened risk of developing hypertension and diabetes, which are both risk factors for kidney disease.

Psychological disorders

One 2022 study, whose findings were reported in “Psoriasis: Targets and Therapy,” found that the mental health fallout from untreated psoriasis included depression, anxiety, substance misuse and suicidal ideation.

As the discussion above shows, psoriasis can have far-reaching effects if it remains untreated or isn’t treated appropriately. These potential complications could be the reason why enterprises such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are working to develop treatments with higher efficacy against psoriasis so that patients don’t get exposed to complications arising from undertreatment of the primary skin condition.

NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Chronic Inflammation Could Be the Missing Key to Understanding Long Covid

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human…

24 hours ago

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has…

2 days ago

Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment

A new study done in India has produced results that bring into question the longstanding assumption that…

3 days ago

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”)…

4 days ago

Study Highlights Increasing Cases of Breast Cancer in Younger Women

A study that involved an analysis of patient records in New York has discovered that…

7 days ago

Health Experts Suggest How Public Trust Can Be Restored in US Healthcare

After the pandemic, public trust in the U.S. healthcare system plummeted, and officials at the…

1 week ago